SL22106: Specialised integrated unit 2: cardiovascular disease and endocrine disorders
[Page last updated: 03 June 2024]
| Academic Year: | 2024/25 |
| Owning Department/School: | Department of Life Sciences |
| Credits: | 10 [equivalent to 20 CATS credits] |
| Notional Study Hours: | 200 |
| Level: | Intermediate (FHEQ level 5) |
| Period: |
|
| Assessment Summary: | CWSG 15%, CWSI 15%, EXCB 70% |
| Assessment Detail: |
|
| Supplementary Assessment: |
|
| Requisites: | |
| Learning Outcomes: |
By the end of the unit, you will be able to:
1. Describe the aetiology, epidemiology, pathophysiology and clinical symptoms of cardiovascular and major endocrine diseases and how they are diagnosed and treated.
2. Identify and utilise evidence-based approaches for the management of cardiovascular and major endocrine disorders.
3. Explain how disease and patient factors affect drug therapy and determine therapy outcomes.
4. Evaluate the evidence base for the management of cardiovascular disease and major endocrine disorders.
5. Describe the role of the pharmacist in prescribing, administering and monitoring medication for patients with cardiovascular and major endocrine disorders.
6. Use risk calculators and be able to make a referral based on a pharmacy-based cardiovascular risk assessment.
7. Make appropriate clinical decisions in support of patients with cardiovascular and major endocrine disorders.
8. Reflect on their own practice in supporting patients with these diseases and identify areas for continuous improvement.
9. Apply structured consultation skills to the conditions studied in this unit. |
| Synopsis: | This unit will provide you with a comprehensive, integrated understanding of the design and development of medicines, their pharmacological actions in the body and the evidence-based approach to management of and prescribing for patients with the aim of promoting safe and effective outcomes in cardiovascular and major endocrine disorders. |
| Content: | Clinical introduction and overview of therapeutic area
Problem-based learning case
Pharmaceutics theme
Peptide & protein delivery, recombinant technologies, insulin production
Multiple dose pharmacokinetics and drug monitoring
Autonomic nervous system pharmacology
Receptor signalling
Regulation of blood pressure
The kidney and diuretics
Atherosclerosis and lipid lowering drugs
Coagulation, anti-platelets and anticoagulants, DVT and pulmonary embolism
Drug design and molecular modelling of drugs to treat cardiovascular disease and endocrine disorders
Cardiac glycosides as natural products
The biochemistry of glucose metabolism and fatty acid metabolism
The management of hypertension
Angina, acute coronary syndromes, myocardial infarction
Heart failure, positive inotropes
Cardiac arrhythmias, anti-arrhythmic drugs
Diabetes types I & II, antidiabetic drugs, insulin delivery
Thyroid & pituitary diseases
Hormone replacement therapy (HRT)
Clinical decision-making in cardiovascular and endocrine diseases.
Simulation and practice-based learning in cardiology
Interprofessional solutions to cardiovascular risk management |
| Course availability: |
SL22106 is a Must Pass Unit on the following courses:Department of Life Sciences
|
Notes:
|